TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ARVN

Arvinas Inc

Healthcare · Biotechnology

8.30$ -0.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement ARVN
Line item 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
343.0% 422.1% 0.0% 12.8% 6.2% 8.5% 2.5% 2.0%
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 98.0%
299.0% 379.9% 315.5% 156.4% 497.0% 386.3% 239.7% 483.7% 132.2% 107.7%
47.9% 46.8% 90.3% 63.5% 175.7% 131.9% 60.6% 127.8% 62.8% 34.0%
347.0% 426.7% 405.8% 219.9% 672.7% 518.2% 300.3% 611.5% 195.0% 141.8%
-247.0% -326.7% -305.8% -119.9% -572.7% -418.2% -200.3% -511.5% -95.0% -43.8%
1.0% 0.7% 0.4% 0.2% 0.3% 0.2% 9.1%
-216.5% -317.3% -289.6% -163.6% -547.4% -409.0% -191.0% -466.8% -75.3% -30.7%
-1.3% 8.0% 16.6% -19.0% -34.6% -16.7% 15.9% 1.1% 0.2% 0.1%
-215.2% -317.3% -289.6% -144.6% -512.7% -392.3% -206.9% -467.9% -75.5% -30.8%
-208.9% -312.1% -300.9% -114.6% -554.2% -405.4% -194.1% -458.2% -72.8% -28.7%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?